Abstract: Ankylosing spondylitis (AS) is a chronic, progressive disease characterized by infl ammation in the spine and sacroiliac joints which causes pain, stiffness and the potential for spinal ankylosis. It is associated with signifi cant functional impairment. It is common and since onset is often in young people, the burden of disease is considerable. Conventional treatment including non-steroidal antiinfl ammatory drugs (NSAIDs) and physiotherapy have proven but limited effi cacy in controlling symptoms and preventing progression of spinal manifestations. Infl iximab, a chimeric monoclonal antibody which binds to and inhibits tumor necrosis factor alpha (TNFα), is highly effective in controlling disease activity in AS. In AS, infl iximab 5 mg/kg body weight is usually given as an infusion at weeks 0, 2 and 6, and then every 6-8 weeks. When infl iximab is used in combination with NSAIDs a rapid improvement in disease activity by at least 50% is seen in as many as 50% of AS patients. Infl iximab has been shown to have ongoing effi cacy for as long as regular infusions continue and is safe in the medium term. Magnetic resonance studies show major reductions in spinal infl ammation during treatment with infl iximab, however ongoing studies will assess if infl iximab has disease modifying effect in AS.
Ankylosing spondylitis (AS) is a chronic systemic infl ammatory arthropathy that primarily affects the axial skeleton. It is the prototype of the spondyloarthritides (SpA), a group of diseases which includes psoriatic arthritis, infl ammatory bowel disease associated arthritis, reactive arthritis and undifferentiated spondyloarthritis. AS usually begins in adolescence or early adulthood, and is two to three times more common in men as in women (Khan 2002) . The incidence varies with geographic location, affecting 0.1%-1.5% of the population (Boonen and van der Linden 2006) . The major clinical features of AS are sacroiliitis and infl ammatory back pain, the later characterized by insidious onset before the age of 45 years, and worsening with inactivity and improving with physical activity. This is associated with impaired spinal mobility, with restriction of fl exion and extension of the lumbar spine and expansion of the chest. Other musculoskeletal features include peripheral arthritis and enthesitis (infl ammation at the sites at which ligaments and tendons insert into bone). These features are refl ected in the modifi ed New York criteria used to establish a diagnosis of AS (Table 1) , which also recognizes radiological evidence of sacroiliitis as the hallmark of AS (van der Linden et al 1984) . Extra-articular manifestations can include constitutional symptoms, acute anterior uveitis (AAU), spinal osteoporosis and aortic valve incompetence. The course of AS is variable but can lead to severe functional impairment due to spinal fusion and hip joint involvement or from extra-spinal manifestations. AS is also associated with unemployment and signifi cant fi nancial cost (Ward 2002; Mau et al 2005; Boonen and van der Linden 2006) .
The goals of management of AS are to relieve pain, stiffness and fatigue, maintain spinal mobility and posture and avoid disability. For over 5 decades the mainstay of therapy has been long-term use of NSAIDs in combination with exercise and physical therapy (Dougados et al 2002) . Although NSAIDs reduce spinal pain and improve function, and physical therapy improves spinal movement, many people with AS continue to have disabling symptoms due to active disease . There is limited evidence that traditional disease modifying antirheumatic drugs (DMARDs) including methotrexate and sulfasalazine may improve peripheral arthritis in AS and sulfasalazine may have a modest benefi t for infl ammatory back pain in patients with relatively mild disease (Braun, Zochling, et al 2006) . In this context, treatment of AS with biological agents which block tumor necrosis factor alpha (TNFα) has been a key therapeutic advance.
TNFα is a pivotal regulator of the expression of other pro-infl ammatory cytokines and is a key mediator of synovial and systemic infl ammation (Feldmann 2001) . Anti-TNFα therapy with the monoclonal antibody infl iximab (Remicade; Centocor Inc., Malvern. PA) was initially demonstrated to be highly effective in treating rheumatoid arthritis refractory to traditional DMARDs (Maini et al 1998 (Maini et al , 1999 Lipsky et al 2000) and refractory fi stulating Crohn's disease (Present et al 1999) . As SpA can be seen in patients with infl ammatory bowel disease, TNFα seemed a potential therapeutic target in AS and subsequently patients with Crohn's disease treated with infl iximab were shown to have an improvement in the peripheral arthritis of infl ammatory bowel disease associated SpA (Van den Bosch, Kruithof, De Vos, et al 2000) . In addition demonstration that the cellular infi ltrate in sacroiliitis had abundant TNFα messenger RNA (Braun et al 1995) and that TNFα was elevated in the serum (Gratacos et al 1994; Toussirot et al 1994) and synovial tissue (Canete et al 1997) of patients with SpA justifi ed pilot studies of infl iximab therapy for AS. Open studies performed simultaneously in Ghent (Van den Bosch, Kruithof, Baeten, et al 2000) and Berlin (Brandt et al 2000) showed rapid and persistent reduction in symptoms of AS with infl iximab therapy which were confi rmed in further open label studies (Stone et al 2001; Maksymowych et al 2002; Breban et al 2002) and observational cohort studies (Brandt et al 2001; Temekonidis et al 2003) using infl iximab in patients with active AS refractory to treatment with NSAIDs.
Infl iximab
Infliximab is a chimeric IgG1 κ monoclonal antibody, composed of human constant regions and the TNFα-specifi c murine variable regions (Knight et al 1993) . Infl iximab is produced by a recombinant cell line cultured by continuous perfusion and is purifi ed by a series of steps that includes measures to inactivate and remove viruses. Infl iximab neutralizes the biological activity of TNFα by binding with high affi nity to the soluble and transmembrane forms of TNFα, preventing association of TNFα with its receptors (Knight et al 1993) . Cells expressing transmembrane TNFα bound by infl iximab are lysed in vitro by both complement and cell mediated lysis (Scallon et al 1995) . Infl iximab inhibits the functional activity of TNFα in a wide variety of in vitro bioassays utilizing human fi broblasts, endothelial cells, neutrophils, B and T lymphocytes and epithelial cells (Siegel et al 1995) . It is supplied as a sterile, white, lyophilized powder, reconstituted with sterile water for intravenous infusion, usually over 1-2 hours. In AS the conventional dose regimen is 5 mg/kg given initially at 0, 2 and 6 weeks, then every 6-8 weeks. Infl iximab is licensed for use in adults; it has not been tested in children.
Considerations relevant to understanding clinical trials in AS
Interpreting clinical trials in AS requires an introduction to classifi cation and outcome measures relevant in AS, including potential limitations. Entry criteria require a defi nite diagnosis of AS according to modifi ed New York criterion (Table 1) , thus all enrolled patients have radiological evidence of sacroiliitis of at least grade 2 bilaterally (early sacroiliitis with minor sclerosis, limited erosions and joint space narrowing) or grade 3 unilaterally (defi nite sacroiliitis with severe sclerosis, clear-cut erosions, joint space narrowing and some ankylosis). As sacroiliitis often takes years to develop, Infl iximab in the treatment of ankylosing spondylitis results from these trials can only be applied to patients with established, longstanding disease. Expert panels have acknowledged that this may exclude patients with early AS who may still benefi t greatly from treatment with infl iximab (Braun, Pham, et al 2003) and the development of diagnostic criteria which include MRI to identify patients with early disease remains an area of active research. For the purpose of enrolment most clinical trials defi ne active disease as a Bath Ankylosing spondylitis activity index (BASDAI) of Ͼ4. Key outcome assessment instruments are outlined in Table 2 .
Response to treatment is generally measured as absolute reduction of any one of the outcomes measures by a predefi ned amount (eg, a reduction in BASDAI of Ն 2) or as a percentage reduction of a composite score. The Assessments in Ankylosing Spondylitis (ASAS) Working Group has defi ned and validated a composite of disease activity and disability called ASAS 20 which requires an improvement of 20% or more and absolute improvement of more than 10 units on a 0-10 scale in the 3 of the 4 domains of patient global, pain, function and infl ammation and no deterioration in the remaining domain (Anderson et al 2001) . Although not specifi cally validated, many trials report proportions of patients reaching ASAS 50 or ASAS 70 (patients reaching a 50% or 70% improvement in the ASAS 20 domains).
Pivotal controlled trials in the treatment of AS
Braun et al conducted a 12-week, multi-center, randomizedcontrolled trial (RCT) of infliximab versus placebo in 70 patients with active AS (Braun et al 2002) . The primary end point was a 50% reduction of disease activity (measured as BASDAI). Fifty-three percent of infl iximab-treated patients achieved this end-point compared with 9% of placebotreated patients, a highly statistically signifi cant difference (p Ͻ 0.001). Improvement was rapid in the infl iximab-treated group with 41% of patients having 50% improvement within 2 weeks. There were also similar improvements in function, spinal mobility and quality of life for the infl iximab group. Infl iximab-treated patients also had reduced use of NSAIDs and reductions in C-reactive protein (CRP) and erythrocyte sedimentation rate. Although infliximab was generally well tolerated, three patients had serious adverse events and were withdrawn from this short study. These included disseminated tuberculosis, high fever and lymphadenopathy with pulmonary infi ltrates. Twenty of these patients enrolled at one centre had spinal magnetic resonance imaging (MRI) of the spine conducted at baseline and week 12, in part to evaluate a new scoring system (Braun, Baraliakos, et al 2003) . Seventy-fi ve percent of patients had active spinal lesions, defi ned as vertebral bone marrow edema and/or erosions, with a 40% improvement seen in the infl iximab group and 6% in placebo group. Reduction in MRI evidence of spinal infl ammation had a strong correlation with the observed clinical improvement in infl iximab-treated patients. At the 12-week conclusion of this trial the 69 completing patients all received treatment with infl iximab 5 mg/kg every 6 weeks and have been followed-up in an open extension trial, the results of which are discussed below.
A contemporaneous RCT included 40 patients with a variety of SpA and included 11 patients with AS and a total of 21 patients with axial disease . Similar reductions in BASDAI, BASFI and spinal pain were observed at 12 weeks in these patients.
The ASSERT trial is the largest placebo-controlled trial of infl iximab for AS, randomizing 279 patients in multiple centres to placebo or infl iximab 5 mg/kg at baseline 2, 6, 12 and 18 weeks (van der Heijde et al 2005). The primary end point was achievement of ASAS 20 at 6 months. The patients were typical of those with active AS, consisting of 80% men with a median age of 40 years and median disease duration of almost 9 years. At 24 weeks 61% of the infl iximab group had achieved an ASAS 20 response, compared to 19% in the placebo arm (p Ͻ 0.001). Again patients receiving infl iximab also showed improvement within 2 weeks, which was sustained through the study period. Signifi cant improvements were observed in the all outcomes measured including disease activity (BASDAI), function (BASFI), mobility (BASMI), chest expansion and quality of life (physical component of SF-36). Although adverse events were common in both treatment groups (82.2% of patients receiving infl iximab and 72.0% of patients receiving placebo) most were mild and did not mandate withdrawal from the trial. The commonest were infections (43% infl iximab versus 36% placebo) and infusion reactions (11% infl iximab versus 9.3% placebo). Seven patients (3.5%) in the infl iximab group had severe adverse events, with the one withdrawal due to myelitis. MRI outcomes have also been evaluated in a sub-set of the patients enrolled in the ASSERT trial (Braun, Landewe et al 2006) . A total of 266 patients had spinal MRI at baseline and 24 weeks, 194 in the infl iximab group and 72 in the placebo group. About 80% of patients had at least one active spinal lesion on MRI at baseline. Images were scored according to a MRI activity score (Braun, Baraliakos, et al 2003) , which assigns a score of 0-6 for vertebrae from C2 to S1 on the presence and extent of bone marrow edema and erosions to give a total score of 0-138. Compared to placebo, more patients in the infl iximab group showed a reduction in infl ammation score and patients in the infl iximab group had a signifi cantly greater improvement in total MRI Activity Scores from baseline to week 24 (5.0 ± 6.2, mean ± SD, median 2.7) than did patients in the placebo group (0.6 ± 3.4, median 0.0) (p Ͻ 0.001).
All of these RCTs required withdrawal of DMARDs. Oral corticosteroids were discontinued before screening, however patients were permitted to continue baseline dose of NSAIDs. This is in contrast to treatment of RA with infl iximab, which requires concomitant treatment with methotrexate, in part to reduce the incidence of human antibodies against the chimeric Infl iximab in the treatment of ankylosing spondylitis parts of the molecule (Human anti-chimera antibodies or HACA) (Moreland et al 1996) . HACA are thought to be responsible for infusion reactions (Baert et al 2003) . In a 30-week double-blind RCT patients treated with infl iximab and low dose methotrexate had a similar low incidence of infusion reactions to patients treated with infl iximab alone, although the incidence of HACA antibodies in each treatment group was not assessed (Marzo-Ortega et al 2005).
Open label extensions
Reports on the open-label extension of the pivotal RCTs of infl iximab therapy for AS show a durability of response. In the extension of the original 3-month RCT, Braun et al reported that of the original 69 patients who received infl iximab after the 12 week end point, 49 (71%) continued infl iximab for 2 years , 43 (62%) for 3 years (Braun, Baraliakos, Brandt, et al 2005) and 41 (59.4%) for 5 years (Baraliakos et al 2006) . All improvements in disease activity were sustained and almost 60% of patients maintained an ASAS 50 over 3 years. Outcomes for 5 years were recently reported in abstract form, confi rming a sustained response (Barakiakos et al 2006) . During the 3-year follow-up up to 96% of patients had adverse events, although these were generally mild with only 11 patients discontinued therapy due to adverse events (Braun, Baraliakos, Brandt et al 2005) . Although the long-term effi cacy of infl iximab has been demonstrated, unfortunately there is a rapid loss of response with discontinuation. Over 60% of patients who have previously had a sustained response to therapy relapse within 4 months of cessation of infl iximab infusions (Baraliakos, Listing, Brandt, et al 2005) . Fortunately all patients retreated responded with resumption of infusions.
Other outcomes
An important outcome measure in trials of therapy for AS is the ability to prevent radiographic progression. Improvement of active spinal lesions over short periods after treatment with infl iximab has been demonstrated by MRI as already discussed but chronic spinal changes are better assessed by plain radiography (Wanders et al 2004) . Comparison of patients treated for 2 years with infl iximab with patients from an AS cohort followed-up for 2 years showed a small, non-signifi cant reduction in radiological changes on lateral lumbar and cervical spine views in the infl iximab treated group as measured with modifi ed Stoke ankylosing spondylitis spine score (Baraliakos, Listing, Rudwaleit, et al 2005) , despite older age, longer disease duration and higher level of radiographic damage at baseline. Although promising, larger studies over longer periods will be required to assess the disease modifying effects of infl iximab.
Enthesitis is one of the most common extra-axial features of the SpA. Neither of the two major RCT enrolling patients with AS demonstrated signifi cant reductions in enthesitis or swollen joint count in infl iximab treated patients, perhaps because the prevalence of extra-axial infl ammation was very low at baseline in both studies (Braun et al 2002 , van der Heijde et al 2005 . However a 12-week RCT of 40 patients with a variety of SpA randomized to receive infl iximab at standard AS dose or placebo did show infl iximab treatment was associated with a statistically signifi cant reduction in peripheral joint pain and tenderness . Infl iximab has also induced a rapid and complete clinical and ultrasonographic resolution of refractory, erosive calcaneal enthesitis in two HLA-B27+ patients after induction treatment with infl iximab 3 mg/kg (D'Agostino et al 2002).
The incidence of AAU appears to be reduced during treatment with infl iximab. Data on 397 patients enrolled in RCT of TNFα-inhibitors showed patients receiving placebo had a mean 15.6 fl ares of AAU/100 patient years compared to 3.4/100 patient years for infl iximab treated patients (Braun, Baraliakos, Listing, et al 2005) .
AS can occur in the context of psoriasis, which in itself is a potentially disabling condition. A Phase III RCT inpatients with moderately severe psoriasis showed infl iximab monotherapy was highly effective in treating both skin and nail psoriasis (Reich et al 2005) .
Osteoporosis leading to spinal fracture is a recognised late complication of AS (Khan 2002) . Two recent studies have reported improvements in bone mineral density (BMD) in patients with AS treated with infl iximab (Allali et al 2003; Marzo-Ortega et al 2005) . Allai et al (2003) measured significant improvements in BMD at the spine (3.6%, p = 0.001) and total hip (2.2%, p = 0.0012) in 29 patients with SpA treated with infl iximab for 6 months. A RCT comparing treatment with infl iximab and methotrexate versus methotrexate alone in 42 patients with AS recorded a 1.9% increase in BMD at the hip (p = 0.04) in the infl iximab group after 30 weeks with non-signifi cant increases in the femoral neck and spine (Marzo-Ortega et al 2005) . In these studies approximately 20% of patients were taking systemic glucocorticoids but these were not discontinued.
Infl iximab treatment of AS has impacts on socio-economic outcome measures. Over the relatively short 6-month period of an RCT, infl iximab treatment was associated with reductions in work absenteeism and work disability . In the open label extension of the Braun study there was a reduction of hospital admissions from 41% in the 12 months prior to enrollment to 10% in the patients completing 2 years of infl iximab therapy . In addition the sub-group of completers who were in paid employment there was a reduction in work absenteeism with the mean number of days sick leave per annum reducing from 31.5 to 12.5 at 1 year and 4.7 days at 2 years. The cost savings of infl iximab therapy were estimated at almost 5000 for each treated patient per year.
Dose
There are no formal dose fi nding studies for infl iximab in AS. The 5 mg/kg dose was chosen as this dose is standard for patients with Crohn's disease and on the basis of a small study which suggested 5 mg/kg was more effective than 3 mg/kg (Braun et al 2002) . Indeed in a cohort of 30 patients with SpA with axial involvement treated 6-weekly with 3 mg/kg infl iximab, two-thirds of patients required an increase in dose or reduction in interval to achieve or maintain a response (Sidiropoulos et al 2005) . In a Canadian cohort including 8 patients treated for 1 year with 3 mg/kg infl iximab every 8 weeks, these patients had maintenance of initial response but two patients required an increased dose of infl iximab to sustain the response (Maksymowych et al 2002) . In a pilot study of 21 patients with a variety of AS related SpA a dosage regimen of 5 mg/kg of infl iximab every 14 weeks ultimately resulted in almost 80% of patients experiencing relapse of disease activity prior to the next infusion . This suggests the 14-week interval was too long. A dosage regimen of 5 mg/kg every 8 weeks has shown sustained achievements of ASAS 50 after 1 year of treatment. Thus most patients will require a dose of 3-5 mg/kg given 6-8 weekly for an adequate and sustained clinical response although there may be a need to individualize dosage or interval based on response.
Safety
The major immunomodulating effect of infl iximab on the immune system raises concerns about the risk of infection, autoantibodies and tumors. The infectious risk associated with infl iximab has been systematically assessed in a cohort of 107 patients with SpA with observations extending over 191.5 patient years of treatment (Baeten et al 2003) . Eight severe infections were observed, including two cases of reactivation of tuberculosis, three retropharyngeal abscesses, one episode of culture-negative sepsis-like syndrome and two procedure-related infections. Reactivation of tuberculosis was also reported in a previously discussed RCT (Braun et al 2002) . The risk of reactivation of tuberculosis during treatment with infl iximab is well documented. Of note, this often occurs within 12 weeks of commencement of therapy, with in excess of 50% of cases being extra-pulmonary, 25% disseminated and almost 50% requiring a biopsy for diagnosis (Keane et al 2001) . Current guidelines recommend screening for active or latent tuberculosis when considering treatment with a TNFα-inhibitor and treatment of latent tuberculosis with prophylactic isoniazid for at least 2 months prior to commencement of infl iximab, with completion of 6-9 months of isoniazid therapy (American Thoracic Society 2000; British Thoracic Society 2005) . Patients treated with infl iximab, and their physicians, should be aware of the increased risk of serious infection and prompt assessment of any symptoms which may suggest infection is warranted. Infl iximab therapy is relatively contraindicated in situations associated with an increased risk of infection including: chronic leg ulceration, septic arthritis of a native joint within 12 months, sepsis of a prosthetic joint within 12 months or indefi nitely if prosthesis remains in situ, persistent or recurrent chest infections (eg, bronchiectasis), and presence of an indwelling urinary catheter (Braun, Pham, et al 2003) .
Clinical trials have shown that infl iximab may induce autoantibodies such as antinuclear antibodies (ANA) and anti dsDNA antibodies (Charles et al 2000) . The occurrence of these antibodies during infl iximab therapy for AS has not been systematically addressed. In one placebo-controlled trial enrolling patients with SpA, 17% were ANA positive and none dsDNA positive at baseline but after 34-weeks of infl iximab therapy 89% were ANA positive and 17% dsDNA positive . No patients had any clinical evidence of lupus-like disease.
Asymptomatic elevation in liver transaminases are commonly observed during treatment with infl iximab and rare cases of acute liver failure and autoimmune hepatitis have been reported (Infl iximab Product Information, Centocor, Malvern PA). Cytopenias have also been observed, although casual association has not been established.
Other contraindications to infl iximab therapy include pregnancy or inadequate contraception in a women of child-bearing potential, breastfeeding, history of lupus or multiple sclerosis, malignancy other than basal cell carcinoma and those treated more than 10 years previously (Braun, Pham, et al 2003) 
Biological modulation
Although there are no studies of a pure AS cohort, there are data regarding the biological effects of infl iximab therapy Infl iximab in the treatment of ankylosing spondylitis in patients with SpA. Patients with SpA appear to have Th2 polarization with decreased T-cell production of IFNγ and IL-2 and increased IL-10 (Yin et al 1999; Baeten, Kruithof, et al 2001; Baeten, Van Damme, et al 2001) . Treatment with infl iximab induced a rapid and sustained increase in T-cell synthesis of IFNγ and IL-2 and transient decrease in IL-10 production (Baeten, Kruithof, et al 2001) restoring Th1/Th2 balance. This data supports the hypothesis that infl iximab reverses the anergic state of Th1 cells. At a tissue level repeated synovial biopsy has allowed an insight into histological changes in synovial pathology in peripheral joints in SpA patients with active synovitis after treatment with infl iximab. After 12 weeks infl iximab reduced synovial layer thickness, endothelial activation (E-selection or VCAM-1) and cellular infi ltration by neutrophils, macrophages and T cells (Baeten, Kruithof, et al 2001; Kruithof et al 2005) . Synovial levels of matrix metalloproteinase-3 (MMP-3) and tissue inhibitors of matrix metalloproteinases (TIMP) are also elevated in SpA synovium and treatment with infl iximab rapidly downregulates synovial expression of MMP-3 and TIMP and serum MMP-3 (Vandooren et al 2004) . Further analysis has shown that reduction in lining and sub-lining macrophages and reduced immature macrophages, sub-lining matrix MMP-3 and neutrophil infi ltration are accurate early predictors of response to treatment, performing as well as changes in acute phase reactants .
Cost effectiveness
As a recombinant biological agent, infl iximab therapy is expensive. Despite the expense, cost-effectiveness modelling in two health-care systems suggest the clinical benefi ts and improvement in quality of life with infl iximab lead to lower disease-associated costs than standard care (Kobelt et al 2004 (Kobelt et al , 2006 and modeling for long-term therapy assuming progression of BASFI sees a further reduction in the cost per quality adjusted life year. Longer term data on disease progression of AS during treatment with infl iximab is required to confi rm this hypothetical data, in addition to measurements of savings in in-direct costs related to work disability and AS-related illness.
Current indications
A consensus statement developed by the ASAS working group gives clear recommendations, based on published literature and expert opinion, about the indication for anti-TNFα therapy in AS (Braun, Pham, et al 2003; Braun, Davis, et al 2006) . For the initiation of therapy the recommendations are 1. A diagnosis of defi nitive AS based on the modifi ed New York criteria; 2. Presence of active disease for at least 4 weeks defi ned by both a sustained BASDAI of at least 4 and expert opinion based on clinical features, acute phase reactants, and imaging modalities; 3. Presence of refractory disease defi ned by failure of at least two NSAIDs during a single 3-month period, failure of intra-articular steroids if indicated, and failure of sulfasalazine in patients with peripheral arthritis; 4. Application and implementation of the usual precautions and contraindications for biological therapy. Discontinuation is recommended if there is a failure to reach at least a 50% or 2-unit improvement (on a 0-10 scale) of the BASDAI at 6-12 weeks or if expert opinion suggests cessation. Most countries will develop local guidelines for therapy, which may be infl uenced by cost considerations as well as published literature. Retrospective analysis of major RCTs suggests that a response to therapy may be predicted by shorter disease duration and less functional disability however the patients included in this analysis had very high disease activity at baseline and these conclusions may not be appropriate to generalize to a real-world treatment situation. A major problem in treatment of AS is the long delay between onset of symptoms and diagnosis (Khan 2002) . This is of particular relevance when response to infl iximab therapy may be improved when therapy is commenced early. Rudwaliet, van der Heijde et al (2004) have proposed a clinical algorithm based on the presence of infl ammatory back pain and assigning likelihood ratios for diagnosis based on the presence of other features of SpA. The presence of infl ammatory back pain and two or three other features of SpA (including enthesitis, alternating buttock pain, peripheral arthritis, dactylitis, AAU, psoriasis, family history of SpA and response to NSAIDs) gave a positive test probability of over 90% for the diagnosis of early SpA. Further clinical trials of infl iximab in patients with probable early AS will be necessary to confi rm therapy is appropriate for these patients but a clinical and perhaps radiological benefi t seems highly probable.
The advent of infl iximab has dramatically increased the therapeutic options for people affected by AS. Infl iximab is highly effective in treating active AS refractory to NSAIDs and some available radiological data suggest a disease modifying effect. Limitations of therapy include potential side effects, particularly serious infection, the cost and the undetermined benefi t in early disease. The cost effectiveness of long-term infl iximab therapy remains to be determined.
